Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
01 2020
Historique:
received: 01 02 2019
accepted: 01 08 2019
pubmed: 8 8 2019
medline: 18 3 2020
entrez: 8 8 2019
Statut: ppublish

Résumé

To determine the frequency, clinical characteristics, associations, and outcomes of different types of peripheral nervous system (PNS) disease in a multiethnic/multiracial, prospective inception cohort of systemic lupus erythematosus (SLE) patients. Patients were evaluated annually for 19 neuropsychiatric (NP) events including 7 types of PNS disease. SLE disease activity, organ damage, autoantibodies, and patient and physician assessment of outcome were measured. Time to event and linear regressions were used as appropriate. Of 1,827 SLE patients, 88.8% were female, and 48.8% were white. The mean ± SD age was 35.1 ± 13.3 years, disease duration at enrollment was 5.6 ± 4.2 months, and follow-up was 7.6 ± 4.6 years. There were 161 PNS events in 139 (7.6%) of 1,827 patients. The predominant events were peripheral neuropathy (66 of 161 [41.0%]), mononeuropathy (44 of 161 [27.3%]), and cranial neuropathy (39 of 161 [24.2%]), and the majority were attributed to SLE. Multivariate Cox regressions suggested longer time to resolution in patients with a history of neuropathy, older age at SLE diagnosis, higher SLE Disease Activity Index 2000 scores, and for peripheral neuropathy versus other neuropathies. Neuropathy was associated with significantly lower Short Form 36 (SF-36) physical and mental component summary scores versus no NP events. According to physician assessment, the majority of neuropathies resolved or improved over time, which was associated with improvements in SF-36 summary scores for peripheral neuropathy and mononeuropathy. PNS disease is an important component of total NPSLE and has a significant negative impact on health-related quality of life. The outcome is favorable for most patients, but our findings indicate that several factors are associated with longer time to resolution.

Identifiants

pubmed: 31390162
doi: 10.1002/art.41070
pmc: PMC6935421
mid: NIHMS1044687
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-77

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : NIAMS NIH HHS
ID : P60 AR064464
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Organisme : CIHR
ID : MOP-88526
Pays : Canada
Organisme : NIAMS NIH HHS
ID : P30 AR072579
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025741
Pays : United States
Organisme : Arthritis Research UK
Pays : United Kingdom
Organisme : NIAMS NIH HHS
ID : K24 AR002138
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR069572
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00002/8
Pays : United Kingdom

Informations de copyright

© 2019, American College of Rheumatology.

Références

Lupus. 2019 Apr;28(4):465-474
pubmed: 30739544
Autoimmun Rev. 2017 Jul;16(7):750-755
pubmed: 28483540
Arthritis Rheum. 2008 Mar;58(3):843-53
pubmed: 18311802
Lupus. 2018 Mar;27(3):501-506
pubmed: 28764617
Clin Rheumatol. 2014;33(10):1459-66
pubmed: 24852670
Arthritis Care Res (Hoboken). 2018 Oct;70(10):1488-1494
pubmed: 29287313
J Rheumatol. 1996 Jan;23(1):87-92
pubmed: 8838514
Rheumatology (Oxford). 2016 Feb;55(2):252-62
pubmed: 26342222
Biomed Res Int. 2014;2014:524940
pubmed: 24864250
Arthritis Rheum. 1999 Apr;42(4):599-608
pubmed: 10211873
Ann Rheum Dis. 2012 Sep;71(9):1502-9
pubmed: 22492779
J Rheumatol. 1997 Jun;24(6):1083-8
pubmed: 9195513
J Rheumatol. 1999 Jan;26(1):97-102
pubmed: 9918248
Lupus. 2006;15(9):606-7
pubmed: 17080917
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Ann Rheum Dis. 2011 Jun;70(6):961-7
pubmed: 21342917
Lupus. 2012 May;21(6):611-5
pubmed: 22323340
Arthritis Rheum. 2001 Oct;45(5):419-23
pubmed: 11642640
Semin Arthritis Rheum. 2011 Oct;41(2):203-11
pubmed: 21641018
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Lupus. 2002;11(4):215-20
pubmed: 12043884
Arthritis Rheumatol. 2014 Apr;66(4):1000-9
pubmed: 24757151
Semin Arthritis Rheum. 2005 Dec;35(3):175-84
pubmed: 16325658
J Clin Neurophysiol. 1999 Mar;16(2):164-8
pubmed: 10359503
Arch Neurol. 2006 Mar;63(3):401-4
pubmed: 16533967
J Rheumatol. 2002 Feb;29(2):288-91
pubmed: 11838846
J Clin Rheumatol. 2001 Oct;7(5):326-31
pubmed: 17039164
Arthritis Rheum. 2008 May 15;59(5):721-9
pubmed: 18438902
Arthritis Rheum. 2007 Jan;56(1):265-73
pubmed: 17195230
Thromb Haemost. 1999 May;81(5):748-57
pubmed: 10365749
Arthritis Care Res (Hoboken). 2018 Oct;70(10):1478-1487
pubmed: 29316357

Auteurs

John G Hanly (JG)

Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada.

Qiuju Li (Q)

University of Cambridge, Cambridge, UK.

Li Su (L)

University of Cambridge, Cambridge, UK.

Murray B Urowitz (MB)

Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.

Caroline Gordon (C)

University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.

Sang-Cheol Bae (SC)

Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.

Juanita Romero-Diaz (J)

Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico.

Jorge Sanchez-Guerrero (J)

Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.

Sasha Bernatsky (S)

McGill University, Montreal, Quebec, Canada.

Ann E Clarke (AE)

University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.

Daniel J Wallace (DJ)

Cedars-Sinai and University of California, Los Angeles School of Medicine.

David A Isenberg (DA)

University College London, London, UK.

Anisur Rahman (A)

University College London, London, UK.

Joan T Merrill (JT)

Oklahoma Medical Research Foundation, Oklahoma City.

Paul R Fortin (PR)

CHU de Québec and Université Laval, Québec City, Québec, Canada.

Dafna D Gladman (DD)

Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.

Ian N Bruce (IN)

Arthritis Research UK Epidemiology Unit, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Centre, and Manchester University NHS Foundation Trust, Manchester, UK.

Michelle Petri (M)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Ellen M Ginzler (EM)

SUNY Downstate Medical Center, Brooklyn, New York.

M A Dooley (MA)

University of North Carolina, Chapel Hill, North Carolina.

Kristjan Steinsson (K)

Landspitali University Hospital, Reykjavík, Iceland.

Rosalind Ramsey-Goldman (R)

Northwestern University and Feinberg School of Medicine, Chicago, Illinois.

Asad A Zoma (AA)

Hairmyres Hospital, East Kilbride, UK.

Susan Manzi (S)

Allegheny Health Network, Pittsburgh, Pennsylvania.

Ola Nived (O)

Lund University, Lund, Sweden.

Andreas Jonsen (A)

Lund University, Lund, Sweden.

Munther A Khamashta (MA)

St. Thomas' Hospital and King's College London School of Medicine, London, UK.

Graciela S Alarcón (GS)

University of Alabama at Birmingham.

Elisabet Svenungsson (E)

Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

Ronald F van Vollenhoven (RF)

Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Cynthia Aranow (C)

Feinstein Institute for Medical Research, Manhasset, New York.

Meggan Mackay (M)

Feinstein Institute for Medical Research, Manhasset, New York.

Guillermo Ruiz-Irastorza (G)

Hospital Universitario Cruces and University of the Basque Country, Barakaldo, Spain.

Manuel Ramos-Casals (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer and Hospital Clínic de Barcelona, Barcelona, Spain.

S Sam Lim (SS)

Emory University School of Medicine, Atlanta, Georgia.

Murat Inanc (M)

Istanbul University, Istanbul, Turkey.

Kenneth C Kalunian (KC)

University of California San Diego School of Medicine.

Soren Jacobsen (S)

Rigshospitalet and Copenhagen University Hospital, Copenhagen, Denmark.

Christine A Peschken (CA)

University of Manitoba, Winnipeg, Manitoba, Canada.

Diane L Kamen (DL)

Medical University of South Carolina, Charleston.

Anca Askanase (A)

NYU Langone Orthopedic Hospital, New York, New York.

Chris Theriault (C)

Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada.

Vernon Farewell (V)

University of Cambridge, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH